Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –– Unaudited 2025 total product and royalty revenue of ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
TipRanks on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
Verywell Health on MSN
6 Supplements That Can Interfere with Blood Sugar Medications
Supplements like berberine, cinnamon, ginseng, and St. John’s Wort can affect how diabetes medications work. Learn the ...
Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
The latest proposal from Ald. Brian Hopkins would let police impose a four-hour "time and place" curfew anywhere in the city ...
Formulas, delivery systems, and active ingredients are getting more sophisticated, so we want to go back to basics, making ...
Background Inflammatory bowel disease (IBD) arises from complex interactions among diet, host and gut microbiome. Although diet influences intestinal inflammation, the microbial and metabolic pathways ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback